Manus Biosynthesis
Latest round
- Series A
Last raised
- Jul 2018
Total raised
- $19M
Investors
- 2
About Manus Biosynthesis
Manus Biosynthesis, Inc.Founded in 2011 and headquartered in Cambridge, US, Manus Bio specializes in creating bioalternatives aimed at replacing petrochemical-derived substances. CEO Ajikumar Parayil, the founder, has a history of entrepreneurial ventures in the biotech field.Manus Bio Inc. specializes in the development and production of bioalternatives, which are sustainable substitutes for traditional ingredients, materials, and chemicals sourced through environmentally harmful methods. The company’s core offerings leverage advanced synthetic biology and microbial cell factories to create a range of products that meet the needs of various industries, including food and beverage, cosmetics, and pharmaceuticals. Their focus on replacing petrochemical-derived substances with bio-based options addresses pressing environmental concerns and aims to enhance supply security for their clients. Manus Bio's flagship products include stevia Reb M, showcased in their partnerships with Tate & Lyle, and other sustainable BioIngredients designed to cater to an expanding market for eco-friendly raw materials.Manus Bio generates revenue through strategic partnerships and direct business-to-business transactions with clients across various sectors. Their business model typically involves collaborations that enable companies to integrate bioalternatives into their existing product lines, allowing clients to benefit from more sustainable and efficient manufacturing processes. Revenue is driven by the sale of custom-engineered microbial solutions and bioingredients, with specific arrangements tailored to meet the needs of each client.Manus Biosynthesis, Inc. plans to accelerate its growth by launching new bioalternative products and expanding into additional markets, specifically increasing its presence in North America and South America by 2023.00 mn will support the development of innovative bioproducts and enhance operational capabilities for scaling production to meet growing market demand.
Who invested in Manus Biosynthesis
2 investors across 1 round
See all investors in Manus Biosynthesis
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Jul 3, 2018
Amount
$19M
Investors
Questions about Manus Biosynthesis
Who invested in Manus Biosynthesis?
Manus Biosynthesis has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Manus Biosynthesis raised?
Manus Biosynthesis has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Manus Biosynthesis last raise money?
Manus Biosynthesis's most recent round on record is a Series A, in Jul 2018.
What does Manus Biosynthesis do?
Manus Biosynthesis is a chemicals company.
Where is Manus Biosynthesis headquartered?
Manus Biosynthesis is headquartered in Cambridge, US.
Which VCs invest in companies like Manus Biosynthesis?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back chemicals companies at Manus Biosynthesis's stage. Their profiles are linked below.
VCs backing chemicals startups at Series A
Raising like Manus Biosynthesis? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.